Form 4: PAVmed Director Glennon Receives 150,000 Restricted Shares

PAVmed Inc. Director Michael J. Glennon was granted 150,000 shares of restricted common stock, aligning his interests with shareholders.

Summary

• Director Michael J. Glennon acquired 150,000 shares of PAVmed Inc. common stock on September 30, 2025.
• The acquisition was a grant of restricted stock under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan.
• The restricted stock was granted at a price of $0 per share.
• These shares are subject to a single vesting date of May 20, 2028.
• The shares are subject to forfeiture if the requisite service period is not completed.
• Following this transaction, Director Glennon beneficially owns 231,667 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates continued alignment of a director's interests with the company's long-term performance through an equity grant, which is a standard compensation practice.

Positives

• The grant of restricted stock aligns Director Michael J. Glennon's long-term interests with those of PAVmed Inc. shareholders.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged and transparent compensation structure.

Risks

• The restricted stock is subject to forfeiture if Director Glennon does not complete the requisite service period before the vesting date of May 20, 2028.

Future Outlook

The restricted stock granted to Director Glennon is scheduled to vest on May 20, 2028, contingent upon the completion of the requisite service period.

Industry Context

Equity grants to directors are a common practice across industries to incentivize long-term commitment and align leadership interests with shareholder value creation. This specific grant is a routine compensation event for a director.

Comparison to Industry Standards

• Equity grants, particularly restricted stock, are a standard component of executive and director compensation packages in publicly traded companies, including those in the medical device and biotechnology sectors where PAVmed operates.
• The use of a 10b5-1 plan for such transactions is also a common corporate governance practice, enhancing transparency and mitigating concerns about insider trading.

Corporate Governance

Related Party Transactions

• The grant of 150,000 shares of restricted common stock to Director Michael J. Glennon constitutes a related party transaction, as it involves compensation to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The grant aims to align the director's financial interests with long-term shareholder value creation, potentially leading to more focused strategic decisions.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation philosophy that can influence overall company culture and retention strategies for key personnel.

Next Steps

• Director Michael J. Glennon must complete the requisite service period for the restricted stock to vest on May 20, 2028.

Key Dates

Keywords

PAVmed, PAVM, Form 4, Insider Transaction, Restricted Stock, Equity Grant, Director Compensation, 10b5-1 Plan